Pub Date : 2024-10-24DOI: 10.1038/s41409-024-02441-w
Z L Zhang, J Tong, R N Lu, A M Scutt, D Goltzman, D S Miao
{"title":"Retraction Note: Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration","authors":"Z L Zhang, J Tong, R N Lu, A M Scutt, D Goltzman, D S Miao","doi":"10.1038/s41409-024-02441-w","DOIUrl":"10.1038/s41409-024-02441-w","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 1","pages":"117-117"},"PeriodicalIF":4.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-024-02441-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-22DOI: 10.1038/s41409-024-02436-7
Ying Wang, Wen-Hui Gao, Li-ning Wang, Ling Wang, Jie-ling Jiang, Ming Wan, Ai-Bin Liang, Didier Blaise, Jiong Hu
Post-transplantation cyclophosphamide (PTCy) has unique advantages for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single-center retrospective landmark analysis, we evaluated chronic GVHD (cGVHD) and clinical outcomes in patients receiving PTCy, tacrolimus, and post-engraftment low-dose anti-thymocyte globulin (PTCy-ATG) as GVHD prophylaxis after HLA-matched unrelated or haploidentical donor transplantation. Two historical patient groups receiving calcineurin inhibitor-based GVHD prophylaxis were used as control groups. A total of 71 patients with myeloid malignancies undergoing allo-HSCT with myeloablative conditioning regimens were included in the analysis. The 3-year cumulative incidences of cGVHD and moderate to severe cGVHD (M/S cGVHD) were 39.2% (95%CI 27.4%–51.0%) and 11.5% (95%CI 4.1%–18.9%), respectively, in the PTCy-ATG group, and only one instance of bronchiolitis obliterans (BO) was observed. The disease-free survival (DFS), overall survival (OS), and GVHD-free and relapse-free survival rates were 94.0% (95%CI 88.3%–99.7%), 93.0% (95%CI 87.1%–98.9%) and 83.8% (95%CI 75.0%–92.6%) respectively. Of note, the PTCy-ATG group presented with a significantly lower incidence of M/S cGVHD and BO, which translated into superior OS in multivariate analysis. In this retrospective analysis, we observed that PTCy-ATG–based GVHD prophylaxis was associated with a lower incidence of M/S cGVHD and better transplantation outcomes beyond day 100, which invites prospective evaluation.
{"title":"Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors","authors":"Ying Wang, Wen-Hui Gao, Li-ning Wang, Ling Wang, Jie-ling Jiang, Ming Wan, Ai-Bin Liang, Didier Blaise, Jiong Hu","doi":"10.1038/s41409-024-02436-7","DOIUrl":"10.1038/s41409-024-02436-7","url":null,"abstract":"Post-transplantation cyclophosphamide (PTCy) has unique advantages for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single-center retrospective landmark analysis, we evaluated chronic GVHD (cGVHD) and clinical outcomes in patients receiving PTCy, tacrolimus, and post-engraftment low-dose anti-thymocyte globulin (PTCy-ATG) as GVHD prophylaxis after HLA-matched unrelated or haploidentical donor transplantation. Two historical patient groups receiving calcineurin inhibitor-based GVHD prophylaxis were used as control groups. A total of 71 patients with myeloid malignancies undergoing allo-HSCT with myeloablative conditioning regimens were included in the analysis. The 3-year cumulative incidences of cGVHD and moderate to severe cGVHD (M/S cGVHD) were 39.2% (95%CI 27.4%–51.0%) and 11.5% (95%CI 4.1%–18.9%), respectively, in the PTCy-ATG group, and only one instance of bronchiolitis obliterans (BO) was observed. The disease-free survival (DFS), overall survival (OS), and GVHD-free and relapse-free survival rates were 94.0% (95%CI 88.3%–99.7%), 93.0% (95%CI 87.1%–98.9%) and 83.8% (95%CI 75.0%–92.6%) respectively. Of note, the PTCy-ATG group presented with a significantly lower incidence of M/S cGVHD and BO, which translated into superior OS in multivariate analysis. In this retrospective analysis, we observed that PTCy-ATG–based GVHD prophylaxis was associated with a lower incidence of M/S cGVHD and better transplantation outcomes beyond day 100, which invites prospective evaluation.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 1","pages":"58-63"},"PeriodicalIF":4.5,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-21DOI: 10.1038/s41409-024-02430-z
Alexandra Gomez-Arteaga, Nora Chokr, Jeffery J. Auletta
In this special issue of Bone Marrow Transplantation, investigators report the impact of IDH1 [1], IDH2 [2], and FLT3-TKD [3] measurable residual disease (MRD) pre-hematopoietic cell transplantation (HCT) in predicting relapse of acute myeloid leukemia (AML) in adults receiving allogeneic HCT. The patient population for these retrospective cohorts, reflecting clinical transplant practice patterns and research biobank participation, was 84–86% non-Hispanic White (NHW) in each study. In this commentary, we explore the implications of racial and ethnic disparities in access to both HCT and HCT-related research and propose strategies to promote representation in precision medicine, given the emerging impact of the field on HCT outcomes.
{"title":"Precision medicine results from equitable representation","authors":"Alexandra Gomez-Arteaga, Nora Chokr, Jeffery J. Auletta","doi":"10.1038/s41409-024-02430-z","DOIUrl":"10.1038/s41409-024-02430-z","url":null,"abstract":"In this special issue of Bone Marrow Transplantation, investigators report the impact of IDH1 [1], IDH2 [2], and FLT3-TKD [3] measurable residual disease (MRD) pre-hematopoietic cell transplantation (HCT) in predicting relapse of acute myeloid leukemia (AML) in adults receiving allogeneic HCT. The patient population for these retrospective cohorts, reflecting clinical transplant practice patterns and research biobank participation, was 84–86% non-Hispanic White (NHW) in each study. In this commentary, we explore the implications of racial and ethnic disparities in access to both HCT and HCT-related research and propose strategies to promote representation in precision medicine, given the emerging impact of the field on HCT outcomes.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 2","pages":"122-127"},"PeriodicalIF":4.5,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1038/s41409-024-02426-9
Whitney Wallis, Alison M. Gulbis, Tao Wang, Catherine J. Lee, Akshay Sharma, Kirsten M. Williams, Taiga Nishihori, Tim Prestidge, Lohith Gowda, Michael Byrne, Maxwell M. Krem, Margaret L. MacMillan, Carrie L. Kitko, Joseph Pidala, Stephen R. Spellman, Stephanie J. Lee, Amin M. Alousi
Bacterial bloodstream infections (BSI) can be a substantial contributor to complications of GVHD treatment. The aim of this study was to determine the risk for BSI from neutrophil engraftment through day 100 post transplant in patients with acute GVHD (AGVHD) based on organ involvement and severity. Patients (n = 4064) who underwent an allogeneic hematopoietic stem cell transplant (HCT) reported to the CIBMTR registry were analyzed. Grade II-IV AGVHD occurred in 1607 (39.5%) patients and was associated with a greater day-100 incidence of post engraftment BSI than with grade 0/I (24.9 vs. 15.3%). Patients with grade III/IV AGVHD had the highest BSI risk (HR 2.45; 95% CI 1.99–3.0; p < 0.0001). Lower GI involvement increased BSI risk (HR 1.54; 95% CI 1.17–2.02; p = 0.0019). BSI post-engraftment through day 100 was associated with worse survival (HR 1.64, 95% CI 1.43–1.87; p < 0.001) and higher non-relapse mortality (NRM), (HR 2.22; 95% CI 1.91–2.59; p < 0.001). Those with stage III/IV GI involvement are at highest risk for BSI. Future studies evaluating novel methods for preventing BSI in these high risk populations are needed to reduce mortality associated with AGVHD.
细菌性血流感染（BSI）可能是导致GVHD治疗并发症的一个重要因素。本研究旨在根据器官受累情况和严重程度，确定急性GVHD（AGVHD）患者从中性粒细胞移植到移植后第100天发生BSI的风险。研究分析了向CIBMTR登记处报告的接受异基因造血干细胞移植（HCT）的患者（n = 4064）。1607例（39.5%）患者发生了II-IV级AGVHD，与0/I级（24.9%对15.3%）相比，II-IV级AGVHD与100天内移植后BSI的发生率更高。III/IV 级 AGVHD 患者的 BSI 风险最高（HR 2.45; 95% CI 1.99-3.0; p
{"title":"Incidence of bacterial blood stream infections in patients with acute GVHD","authors":"Whitney Wallis, Alison M. Gulbis, Tao Wang, Catherine J. Lee, Akshay Sharma, Kirsten M. Williams, Taiga Nishihori, Tim Prestidge, Lohith Gowda, Michael Byrne, Maxwell M. Krem, Margaret L. MacMillan, Carrie L. Kitko, Joseph Pidala, Stephen R. Spellman, Stephanie J. Lee, Amin M. Alousi","doi":"10.1038/s41409-024-02426-9","DOIUrl":"10.1038/s41409-024-02426-9","url":null,"abstract":"Bacterial bloodstream infections (BSI) can be a substantial contributor to complications of GVHD treatment. The aim of this study was to determine the risk for BSI from neutrophil engraftment through day 100 post transplant in patients with acute GVHD (AGVHD) based on organ involvement and severity. Patients (n = 4064) who underwent an allogeneic hematopoietic stem cell transplant (HCT) reported to the CIBMTR registry were analyzed. Grade II-IV AGVHD occurred in 1607 (39.5%) patients and was associated with a greater day-100 incidence of post engraftment BSI than with grade 0/I (24.9 vs. 15.3%). Patients with grade III/IV AGVHD had the highest BSI risk (HR 2.45; 95% CI 1.99–3.0; p < 0.0001). Lower GI involvement increased BSI risk (HR 1.54; 95% CI 1.17–2.02; p = 0.0019). BSI post-engraftment through day 100 was associated with worse survival (HR 1.64, 95% CI 1.43–1.87; p < 0.001) and higher non-relapse mortality (NRM), (HR 2.22; 95% CI 1.91–2.59; p < 0.001). Those with stage III/IV GI involvement are at highest risk for BSI. Future studies evaluating novel methods for preventing BSI in these high risk populations are needed to reduce mortality associated with AGVHD.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 1","pages":"52-57"},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1038/s41409-024-02442-9
Zachary M. Avigan, Suzanne Arinsburg, Darren Pan, Tomer Mark, Christopher Fausel, Joseph Bubalo, Gary Milkovich, Erin Moshier, Weijia Fu, Ajai Chari, Joshua Richter
{"title":"Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma","authors":"Zachary M. Avigan, Suzanne Arinsburg, Darren Pan, Tomer Mark, Christopher Fausel, Joseph Bubalo, Gary Milkovich, Erin Moshier, Weijia Fu, Ajai Chari, Joshua Richter","doi":"10.1038/s41409-024-02442-9","DOIUrl":"10.1038/s41409-024-02442-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 1","pages":"115-115"},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-024-02442-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1038/s41409-024-02435-8
Olaf Penack, Christophe Peczynski, William Boreland, Jessica Lemaitre, H. Christian Reinhardt, Ksenia Afanasyeva, Daniele Avenoso, Tobias A. W. Holderried, Brian Thomas Kornblit, Eleni Gavriilaki, Carmen Martinez, Patrizia Chiusolo, Maria Caterina Mico, Elisabeth Daguenet, Stina Wichert, Hakan Ozdogu, Agnieszka Piekarska, Francesca Kinsella, Grzegorz W. Basak, Hélène Schoemans, Christian Koenecke, Ivan Moiseev, Zinaida Peric
{"title":"Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party","authors":"Olaf Penack, Christophe Peczynski, William Boreland, Jessica Lemaitre, H. Christian Reinhardt, Ksenia Afanasyeva, Daniele Avenoso, Tobias A. W. Holderried, Brian Thomas Kornblit, Eleni Gavriilaki, Carmen Martinez, Patrizia Chiusolo, Maria Caterina Mico, Elisabeth Daguenet, Stina Wichert, Hakan Ozdogu, Agnieszka Piekarska, Francesca Kinsella, Grzegorz W. Basak, Hélène Schoemans, Christian Koenecke, Ivan Moiseev, Zinaida Peric","doi":"10.1038/s41409-024-02435-8","DOIUrl":"10.1038/s41409-024-02435-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 1","pages":"114-114"},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-024-02435-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1038/s41409-024-02444-7
Pranay S. Hegde, Georgia Andrew, Gege Gui, Niveditha Ravindra, Devdeep Mukherjee, Zoë C. Wong, Jeffery J. Auletta, Firas El Chaer, Adam Corner, Steven M. Devine, Antonio Martin Jimenez Jimenez, Marcos J. G. De Lima, Mark R. Litzow, Partow Kebriaei, Wael Saber, Stephen R. Spellman, Scott L. Zeger, Kristin M. Page, Laura W. Dillon, Christopher S. Hourigan
{"title":"Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia","authors":"Pranay S. Hegde, Georgia Andrew, Gege Gui, Niveditha Ravindra, Devdeep Mukherjee, Zoë C. Wong, Jeffery J. Auletta, Firas El Chaer, Adam Corner, Steven M. Devine, Antonio Martin Jimenez Jimenez, Marcos J. G. De Lima, Mark R. Litzow, Partow Kebriaei, Wael Saber, Stephen R. Spellman, Scott L. Zeger, Kristin M. Page, Laura W. Dillon, Christopher S. Hourigan","doi":"10.1038/s41409-024-02444-7","DOIUrl":"10.1038/s41409-024-02444-7","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 2","pages":"175-177"},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-024-02444-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：